A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Early Lumbar Disc Degeneration
Interventions
DRUG

Intradiscal rhGDF-5

The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.

Trial Locations (3)

2217

St. George Private Hospital, Kogarah

2292

Hunter Clinical Research, Broadmeadow

4066

BrizBain & Spine, The Wesley Hospital, Auchenflower

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen-Cilag Pty Ltd

INDUSTRY

lead

DePuy Spine

INDUSTRY